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ABSTRACT
Runx2 is a metastatic transcription factor (TF) in-
creasingly expressed during prostate cancer (PCa)
progression. Using PCa cells conditionally express-
ing Runx2, we previously identified Runx2-regulated
genes with known roles in epithelial–mesenchymal
transition, invasiveness, angiogenesis, extracellular
matrix proteolysis and osteolysis. To map Runx2-
occupied regions (R2ORs) in PCa cells, we first
analyzed regions predicted to bind Runx2 based
on the expression data, and found that recruitment
to sites upstream of the KLK2 and CSF2 genes was
cyclical over time. Genome-wide ChIP-seq analysis
at a time of maximum occupancy at these sites
revealed 1603 high-confidence R2ORs, enriched
with cognate motifs for RUNX, GATA and ETS TFs.
The R2ORs were distributed with little regard to
annotated transcription start sites (TSSs), mainly in
introns and intergenic regions. Runx2-upregulated
genes, however, displayed enrichment for R2ORs
within 40kb of their TSSs. The main annotated func-
tions enriched in 98 Runx2-upregulated genes with
nearby R2ORs were related to invasiveness and
membrane trafficking/secretion. Indeed, using
SDS–PAGE, mass spectrometry and western
analyses, we show that Runx2 enhances secretion
of several proteins, including fatty acid synthase
and metastasis-associated laminins. Thus,
combined analysis of Runx2’s transcriptome and
genomic occupancy in PCa cells lead to defining
its novel role in regulating protein secretion.
INTRODUCTION
The mammalian Runx family includes three transcrip-
tion factors that regulate cellular commitment and
differentiation in several systems including hematopoeisis
(Runx1), skeletogenesis (Runx2) and gastric epithelium
development (Runx3) (1–4). Runx proteins also play
positive and negative roles in carcinogenesis, with Runx2
emerging as a master regulator of tumor metastasis (5,6).
The interest in its pro-metastatic activity initiated with the
idea that expression of Runx2, an osteoblast master regu-
lator (7,8), in prostate cancer (PCa) and breast cancer
(BCa) cells could explain their high predilection to the
skeleton (9). In fact, accumulative evidence now implicates
Runx2 not only in bone targeting, but also in various
other aspects of metastasis. Nuclear Runx2 is increased
in malignant versus benign prostate tissue and is
associated with tumor aggression in general and metasta-
sis in particular (10,11). In animal models of carcinogen-
esis, increased Runx2 levels were observed early during the
development of various malignancies, including PCa (12)
and thyroid cancer (13). Mechanistically, Runx2 has been
shown to promote epithelial–mesenchymal transition
(EMT) and invasiveness, as well as survival in the bone
environment (14,15). Thus, Runx2 plays a variety of roles
during both early and late stages of cancer metastasis,
including but not limited to bone metastasis.
Runx2 stimulates the expression of numerous genes
with known roles in cancer metastasis (5,14–16). Among
them are SOX9, LCN2 and SNAI2, which promote EMT;
MMP9, MMP13 and PGC which play roles in extracellu-
lar matrix degradation and invasiveness; VEGFA and
EDN2, which are important for angiogenesis; and
RANKL, PTHrP, IL8, SPHK1, EDG3 and CSF2, which
likely contribute to the osteolytic phenotype induced by
Runx2-expressing cancer cells that metastasize to bone
(5,14). To gain a better understanding of Runx2’s mech-
anisms in PCa, we performed Runx2 ChIP-seq analysis
using C4-2B/Rx2
dox cells, in which Runx2 expression is
inducible by doxycycline (14). Combined analysis of
gene expression proﬁles and the genomic Runx2 occu-
pancy data led to the identiﬁcation of a subset of
Runx2-responsive genes with nearby Runx2-occupied
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are related not only to cellular properties already
associated with Runx2, such as invasiveness, but also to
the secretory machinery, whose stimulation by Runx2 may
facilitate cell–cell and cell–matrix interactions that
promote metastasis.
MATERIALS AND METHODS
Cell culture
We previously described the cell lines C4-2B/Rx2
dox,
LNCaP/Rx2
dox and MCF7/Rx2
dox, which express Flag-
Runx2 in response to doxycycline (dox); C4-2B/Rx2-
M
dox, which expresses a DNA-binding deﬁcient mutant
of Runx2 in response to dox; and T47D/shRx2
dox,
which knocks down endogenous Runx2 in response to
dox (14,15,17). C4-2B/Rx2
dox, C4-2B/Rx2-M
dox,
LNCaP/Rx2
dox and T47D/shRx2
dox cells were maintained
in RPMI medium and MCF7/Rx2
dox cells were main-
tained in DMEM, each supplemented with 10% FBS.
Dox was added in fresh medium at 0.5mg/ml.
Gene expression analysis
The GEO data set GSE24261, containing gene expression
proﬁles of C4-2B/Rx2
dox cells treated in quadruplicate
with dox or vehicle (14) was re-analyzed using statis-
tical methods described previously (18). Brieﬂy, differen-
tially expressed genes were identiﬁed using Benjamini–
Hochberg adjusted t-test comparing cells treated with
dox or vehicle for either 1 or 2 days. To validate
Runx2-responsiveness of individual genes of interest in
independent cultures, RNA was isolated using the
Bio-Rad Total RNA kit, and cDNA was made using
Quanta qScript cDNA synthesis kit. qPCR was performed
using a Bio-Rad CFX96 machine, Fermentas Maxima
SYBR mastermix and the primers listed in Supplementary
Table S1. Ampliﬁcation reactions had efﬁciency of
90–110% and no primer-dimers were produced. Relative
expression was calculated using the delta Ct method.
Chromatin immunoprecipitation-PCR
Flag-ChIP for Runx2 was carried out essentially as
described for the androgen receptor (19) with the follow-
ing modiﬁcations. C4-2B/Rx2
dox cultures containing
5 10
7 cells were crosslinked in 1.5% formaldehyde for
10min at room temperature, and crosslinking was then
halted by addition of glycine to 125mM. Chromatin was
sonicated to yield 500–1000bp fragments in a buffer con-
taining 50mM Tris–HCl (pH 8.0), 0.1% SDS and 2mM
EDTA. Following preclearing with protein A dynabeads
(Invitrogen), chromatin was incubated overnight with
0.5mg Flag M2 antibody (Sigma) at +4 C and
immunocomplexes were pulled down with Protein A
dynabeads. Crosslinks for both ChIP and input DNA
were reversed at 65 C for 5h and DNA was cleaned
using Qiagen QIAQuick spin DNA kit. Precipitated frag-
ments were quantiﬁed by qPCR as described earlier, and
percentage input values were corrected for negative
control regions when indicated.
ChIP-sequencing and peak calling
Runx2 ChIP DNA along with ChIP input DNA were
prepared as above from C4-2B/Rx2
dox cells treated with
dox for 14h, and high throughput sequencing of the
500–1000bp fragments was performed using Illumina
Hi-Seq 2000. Libraries for ChIP-seq were prepared follow-
ing protocols recommended by Illumina. Enrichment
for known target sequences was veriﬁed by qPCR before
ChIP and input DNA were sequenced. A total of
98165959 and 92795549 sequences were generated for
input and ChIP samples, respectively. MAQ (20) was
used to generate 95514565 and 70493488 alignments to
the hg18 reference genome. These alignments were reduced
to 78152251 and 11371023 after ﬁltering for only uniquely
mapable positions in the genome (Mapping quality score
 20) and condensing multiple reads aligned to identical
positions in the genome (i.e. potential PCR duplicates) to
a single count. Peak Calling was performed using
FindPeaks 4.0 (21), with the ChIP input used as control.
Brieﬂy, using the ﬁltered BAM alignment ﬁles for Runx2
and input, FindPeaks ﬁrst searches for peaks in ChIP
sample, then assesses each peak for enrichment relative to
the Input control. It performs this by normalizing the two
distributions globally using linear regression, and then
modeling the background as a Poisson distribution about
the regression line. Length of fragments was inferred using
the FindPeaks ‘triangle’ distribution. Runx2 peaks with P
values <10
 10 were identiﬁed as R2OR and used for down-
stream analyses. ChIP and input reads have been uploaded
to the Sequence Read Archive, accession SRA048119.2 and
to GEO, Accession GSE33889.
R2OR genomic distributions
Genomic distribution of R2ORs relative to gene annota-
tions was performed using annotations from the UCSC
knownGenes annotation track (hg18). For each annota-
tion comparison, R2OR values were shown side by side
with a set of regions picked randomly from the genome,
with the randomized regions having the same number,
distribution among different chromosomes and size as
the actual R2ORs. One thousand such randomized sets
were generated, and empirical background distributions
were generated from this set of 1000 trials, from which
summary statistics are shown in all comparisons.
Motif discovery and analysis
De novo motif discovery was performed using HOMER
[script v3.1 (05-25-2011)] as previously described (22).
Brieﬂy, R2OR and background genomic sequences were
extracted using Galaxy (23,24) and were divided into
‘target’ and ‘background’ sets for each application of the
algorithm (HOMER perl script ‘ﬁndMotifs.pl’). Motifs of
length 6, 7, 8, 9, 10, 11 and 12bp were identiﬁed separately
for enrichment in ‘target’ compared to ‘background’ set
using the cumulative hypergeometric distribution to score
enrichment. To increase sensitivity of the method, up to
two mismatches were allowed in each oligonucleotide
sequence and distributions of CpG content in ‘target’
and ‘background’ sequences were selectively weighted to
Nucleic Acids Research,2012, Vol.40, No. 8 3539equalize the distributions of CpG content in both sets.
HOMER perl script ‘annotatePeaks.pl’ (22) and R
software [R version 2.13.1, 2011-07-08, (25)] plus
‘ggplot2’ package (26) were used to generate genomic dis-
tribution of each identiﬁed motif. Additional statistical
tools included the Database for Annotation,
Visualization and Integrated Discovery (DAVID) and
NextBio
TM. All statistical tests were done using R
software [R version 2.13.1, 2011-07-08, (25)] and
packages in Bioconductor (27).
Protein analyses
Western blot analysis was performed as previously
described (14) with the following antibodies: Flag M2
from Sigma, GAPDH and FAS (h-300) from Santa
Cruz Biotech, Laminin B1 (ab44941) and Laminin C1
(ab69632) from Abcam, LAMA5 (2F7) from Abnova
and Tubulin from the Developmental Studies
Hybridoma Bank. For mass spectrometry analysis of con-
ditioned medium, C4-2B/Rx2
dox cells were treated with
dox or vehicle for 48h in complete growth media
followed by 24h in serum-free media. Non-adherent cells
were removed from the culture supernatant by brief cen-
trifugation, and proteins precipitated with 20% trichloro-
acetic acid were resolved by SDS–PAGE and stained with
Coomassie Blue. Gel slices of interest were subjected to
in-gel trypsin digestion as described (28). The resulting
peptides were cleaned using C18 OmixTips (Varian) and
analyzed by the Proteomics Facility at Childrens Hospital
Los Angeles essentially as previously described (29)
using an Eksigent nanoLC-2D coupled to a Thermo
Orbitrap XL mass spectrometer. Proteins were identiﬁed
from tandem mass spectra by comparison to the human
Uniprot database (downloaded 200908) using complemen-
tary protein identiﬁcation software systems, Bioworks
3.3.1 (Thermo) and Scaffold 3 (Proteome Software)
(30). Protein identiﬁcation was based on at least two
peptides, with peptide and protein probabilities of at
least 95%.
RESULTS
Runx2 binds its targets in a cyclical fashion
Unlike most PCa tumors, the LNCaP and C4-2B cell lines
are essentially Runx2-negative, providing a close-to-zero
background system for the investigation of Runx2
function in PCa. In C4-2B/Rx2
dox and LNCaP/Rx2
dox
cells, Flag-Runx2 is expressed in response to dox at
levels comparable to or lower than those seen in other
PCa cells and osteoblasts (14). Prior to performing
Runx2 ChIP-seq in C4-2B/Rx2
dox cells, and because
there are relatively few published studies of Runx2 ChIP
in general and in PCa cells in particular, we ﬁrst optimized
our ChIP assay based on Runx2 occupancy upstream of
the CSF2 and KLK2 genes (Figure 1A). We chose these
regions because CSF2 and KLK2 were strongly stimulated
by Runx2 in C4-2B/Rx2
dox cells (14), and because they
contained clusters of Runx motifs (Figure 1A), a feature
thought to constitute strong binding sites for Runx
transcription factors (31,32). Runx2 binding upstream of
the CSF2 and KLK2 genes was tested by quantitative
ChIP assays every 2h between 12 and 24h of Runx2
induction. A cyclical binding pattern of Runx2 was
obvious (Figure 1B), even though the protein level of
Runx2 did not change signiﬁcantly (Figure 1C).
Untreated C4-2B/Rx2
dox cells were processed in parallel;
because they do not express Flag-Runx2, they serve as an
ideal negative control for our ChIP experiments. As
shown in Figure 1B, Flag-ChIP of the untreated cells
did not show any enrichment at the CSF2 and KLK2
versus the negative control regions, indicating high speci-
ﬁcity of the Flag-ChIP assay.
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Figure 1. Cyclical genomic recruitment of Runx2 to KLK2 and CSF2.
(A) Diagram depicting predicted Runx binding sites within the 5-kb
sequences upstream of the KLK2 and CSF2 TSSs. Runx motifs that
appear as clusters are shown, with red and blue tics representing con-
sensus binding sites with high (>9) and medium scores (<9, >6), re-
spectively, according to the Runx1 matrix from JASPAR. Horizontal
bars indicate the areas targeted for Runx2 ChIP-qPCR analysis. (B)
Runx2 ChIP-qPCR time course analysis for binding to the Runx motifs
upstream of the KLK2 (red) and CSF2 TSSs (blue). C4-2B/Rx2
dox cells
were fed fresh medium without (open boxes) or with 0.5mg/ml dox
(closed boxes) and harvested at the indicated time points for ChIP
assay using anti-Flag antibodies. Data points (mean±SEM; n=3)
depict enrichment values corrected for the average of two negative
control regions (triangles, dashed line). The raw values for the KLK2
and CSF2 Runx2 ChIPs oscillated within the 0.15–0.28% and the 0.04–
0.16% input range, respectively, compared to 0.006–0.030% input for
the negative control regions and the ChIPs obtained without
FLAG-Runx2 induction. Results shown are representative of three in-
dependent experiments using separate chromatin preparations. (C)
Western blot analysis of Flag-Runx2 in cells treated in parallel to
those used in B, with GAPDH serving as a loading control.
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For genome-wide mapping of R2ORs, Illumina high
throughput single end sequencing was performed on a
large-scale Runx2 ChIP, in which the CSF2 and KLK2
upstream Runx motifs were enriched by 8- and
16.5-fold, respectively. High throughput sequencing
resulted in approximately 11 million sequence tags that
uniquely mapped to the human genome build 18. As a
control, the input DNA material was also subjected to
high throughput sequencing, resulting in 78 million tags
that were uniquely mapped. We initially examined the
ChIP-seq data for Runx2 occupancy at the KLK2 and
CSF2 loci (Figure 2A). In both cases, several R2ORs
were readily identiﬁed, some with more occupancy than
the regions initially selected for the conventional ChIP
assays (black bars in Figures 1A and 2A). At both loci,
Runx2 occupancy occurred at presumed enhancer
elements as well as at the transcription start sites (TSSs).
Using the FindPeaks program (21), we identiﬁed in the
C4-2B cell genome 5413 R2ORs with an FDR-adjusted P-
value <0.01 (Supplementary Table S2). Among them,
some were found in the vicinity of genes previously
shown to be regulated by Runx2 in PCa and other cell
types, including CXCL12, MMP9, VEGFA and DUSP1
(14), PLAC8 and CRISPLD2 (15), HEY1 and TNC (33)
as well as RUNX1, RUNX3 and RUNX2 itself
(Supplementary Figure S1). Runx2 occupancy at rRNA
genes (34) could not be assessed because these gene se-
quences are highly repetitive and thus not unequivocally
mapped to the hg18 human genome build used in our
study.
For further analyses, we applied a more stringent
FDR-adjusted P-value of 10
 10 resulting in 1603 peaks
that included KLK2, but not CSF2 R2ORs (Supple-
mentary Table S3). We then tested biological reproduci-
bility of Runx2 occupancy at 16 regions by quantitative
PCR (qPCR) of independent chromatin immunopre-
cipitates. Occupancy was conﬁrmed in every case
(Supplementary Figure S2A). Furthermore, when plotted
against peak scores, the qPCR values were in good agree-
ment with the ChIP-seq data (Figure 2B). In addition to
the validation of Runx2 ChIP-seq peaks in C4-2B/Rx2
dox
cells, we analyzed in a similar fashion the related LNCaP/
Rx2
dox PCa cell line (14) and observed Runx2 occupancy
at all 16 sites (Supplementary Figure S2B). Finally, the
speciﬁcity of our results was tested by measuring occu-
pancy of 10 R2ORs by a DNA-binding incompetent
Runx2 mutant (14). Flag-ChIP assays of C4-2B/
Rx2-M
dox cells, which inducibly express the Flag-tagged
Runx2 mutant, showed that in contrast to wild-type
Runx2, the mutant form did not bind to any of the
R2ORs (Supplementary Figure S2C).
Next we assessed the distribution of the 1603 stringently
deﬁned R2ORs in relation to RefSeq gene annotations.
As shown in Figure 2C, the distribution of R2ORs with
respect to nearest TSSs is very similar to the distribution
of matched random sets of genomic sequences, with
R2ORs having a slight preference for TSSs. The vast
majority of R2ORs are located in introns (44%) and
distal intergenic regions (50%) with only 2% at promoters
(Figure 2D). Thus, similar to Runx1 in differentiating
megakaryocytes (35) and in hematopoietic progenitor
cells (36), Runx2 in PCa cells appears to primarily associ-
ate with enhancers and not promoters.
Motif analysis
The three mammalian RUNX proteins have highly hom-
ologous DNA-binding domains and therefore bind similar
consensus TGTGGT motifs in vitro. De novo motif-ﬁnding
analysis of the 1603 top R2ORs in C4-2B/Rx2
dox cells
revealed the highest enrichment for the YTGTGGTTW
sequence, containing the TGTGGT consensus as a core
(Figure 3A). Eighty-one percent of the R2ORs in C4-2B/
Rx2
dox cells contained this sequence (Figure 3C), which is
similar to that found for Runx1 in hematopoietic cells
(35–37) (Figure 3A). Following the remarkable but
expected enrichment of the R2ORs for the classical
Runx motif (P=10
 699), additional de novo motif
analysis indicated strong enrichment (P<10e
 100) for
the GATA consensus motif, AGATAA, as well as a
motif representing a hybrid of Runx and Ets cognate se-
quences (Figure 3B). The GATA and the Runx/Ets motifs
were found in 26% and 6% of R2ORs, respectively
(Figure 3C). Both GATA and ETS transcription factors
have been previously reported to physically interact with
RUNX proteins (35–42).
Runx2-induced genes with nearby R2ORs are functionally
related to protein secretion
Although R2ORs are generally far from TSSs, we asked
whether they were speciﬁcally enriched near TSSs of
Runx2-responsive genes. We ﬁrst re-analyzed our
genome-wide expression data (14) and generated four
sets of genes, those up- or down-regulated after 1 or 2
days of Runx2 induction (FDR-adjusted P<10
 3;
Supplementary Figure S3). For each gene set, we plotted
the histogram of distances between the responsive TSSs
and the nearest R2ORs (Figure 4 and Supplementary
Figure S4). To control for the responsive TSSs, we
generated multiple random size-matched sets of TSSs,
and subjected them to the same analysis. A remarkable
enrichment for R2ORs was observed within  40kb of
the TSSs of upregulated, but not downregulated, genes
(Figure 4 and Supplementary Figure S4). Supplementary
Table S4 lists 98 upregulated genes with nearby (<40kb)
R2ORs, presumably direct Runx2 targets.
To ascertain the functional signiﬁcance of the 98
Runx2-upregulated genes with nearby R2ORs, we
carried out pathway analysis using DAVID (43). The
top functional pathways enriched in this gene set related
to cell attachment and invasion functions (Supplementary
Table S5), consistent with the established role of Runx2 in
metastasis (5,14,16). In addition, DAVID analysis of the
98-gene set highlighted membrane trafﬁcking and secre-
tion as a potential Runx2 target pathway (Figure 5A
and Supplementary Table S5). In particular, Runx2-
upregulated genes with nearby R2ORs coded for
enzymes that modify membrane lipids and small
GTPases of the Rab family, major components of the
Nucleic Acids Research,2012, Vol.40, No. 8 3541secretory pathway (Figure 5A) (44–47). ChIP-seq results
showing R2ORs near the TSSs of RAB3B, RAB43 and
RAB35 are presented in Figure 5B. Validation of these
R2ORs in independent ChIP experiments, as well as inde-
pendent validation of Runx2-mediated upregulation of
RAB3B, RAB43 and RAB35 mRNA are presented in
Figure 5C and D, respectively.
Based on the results of the integrated analysis of Runx2
occupancy and the Runx2 transcriptome, we next asked
whether Runx2 regulated protein secretion by cancer
cells. C4-2B/Rx2
dox cells were treated with either vehicle
as control or dox to induce Runx2, and proteins in con-
ditioned media were visualized by SDS–PAGE and
Coomassie Blue staining. Compared to control cultures,
Figure 2. Genome-wide characterization of Runx2 occupied regions (R2ORs). C4-2B/Rx2
dox cells were subjected to Runx2 ChIP-seq analysis after
dox treatment and immunoprecipitation of Runx2-bound DNA fragments with anti-FLAG antibodies. (A) ChIP-seq results showing R2ORs
upstream of the KLK and CSF2 TSSs. Raw ChIP-seq data are presented as frequency of reads per location for 30kb of DNA sequences at the
KLK2 (top) and CSF2 (bottom) loci. For each locus, the upper track shows results for chromatin aliquoted prior to immunoprecipitation (input).
Regions investigated in Figure 1 by conventional ChIP assays are marked by black bars. (B) Sixteen Runx2 ChIP-seq peaks were validated by
conventional ChIP-qPCR and the ChIP-seq scores are plotted against the qPCR enrichment factors. (C) Distance from the 1603 top R2ORs to the
nearest TSS were mapped (red) and are shown along with control distribution patterns of 1000 sets of 1603 matched random sequences (gray). Y-axis
values are numbers of R2ORs per 15kb window. (D) Genomic distribution of the 1603 top R2ORs (red bars) versus that of 1000 sets of matched
random sequences (gray bars; mean±SD). TSS refers to  1000 to+100bp from 50-end of annotated RNA. Transcription Termination Site (TTS)i s
deﬁned as  100 to +1000bp from the 30-end of the transcript. Inset shows blow up of TTS and TTS data.
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exhibited dramatically increased levels of several secreted
proteins (Figure 6A). The inﬂuence of Runx2 on pro-
tein secretion was also tested in breast cancer cells.
As shown in Supplementary Figure S5, Runx2 expression
enhanced protein secretion by the breast cancer cell
line MCF7/Rx2
dox; and, Runx2 knock-down in the
Runx2-positive T47D cell line inhibited protein secretion.
Thus, Runx2 appears to induce a secretory phenotype
in both prostate and breast cancer cells, potentially
contributing to its pro-metastatic property.
Runx2 particularly augmented the secretion of high
molecular weight proteins (Figure 6A). To identify
some of them, we analyzed by mass spectrometry
proteins with MW >120kDa present in medium condi-
tioned by dox-treated C4-2B/Rx2
dox cultures (bracket in
Figure 6A). Sixteen proteins were identiﬁed with 95% con-
ﬁdence (Supplementary Table S6). Of the respective
mRNAs, only three were upregulated by Runx2
(Supplementary Table S6), and among the remaining 13
proteins, 4 of particular interest were subjected to western
blot analysis. As shown in Figure 6B, fatty acid synthase
(FAS), which is abundantly expressed by PCa cells and
serves as a serum marker for cancer progression (48–50),
was readily detectable in medium conditioned by
Runx2-expressing C4-2B cells, but not in control condi-
tioned medium. Because FAS levels were comparable
between the respective cell extracts (Figure 6B), we
conclude that Runx2 stimulated FAS secretion. More
interestingly, the 16 proteins identiﬁed by mass spectrom-
etry included the laminins a5 (LAMA5), b1 (LAMB1) and
g1 (LAMC1), which together constitute the laminin 511
heterotrimer, strongly implicated in cancer cell motility
(51). Of these three laminins, Runx2 robustly stimulated
the secretion of LAMA5 and LAMB1 while having no
or little effect on the respective cellular protein levels
(Figure 6B). Because LAMC1 was equally present in
media from dox-treated and control cultures (Figure
6B), the data suggest that Runx2-mediated LAMA5 and
LAMB1 secretion may facilitate the assembly of the meta-
static laminin 511 in prostate cancer cells. In summary,
bioinformatics analysis of Runx2 target genes with
nearby R2ORs suggested a role in regulating protein se-
cretion, and such a role was indeed demonstrated for
Figure 4. R2ORs are enriched close to TSS of upregulated genes. Analysis of the distances between the TSSs of differentially expressed genes and
their respective nearest R2ORs was performed for genes whose expression changed after 24h of Runx2 induction (Supplementary Figure S3). The
distances were assigned to 10kb windows, and the number of genes in each window (red dots) was plotted for the up (top) and down (bottom)-
regulated genes. One thousand size-matched random gene sets were analyzed in a similar fashion to generate the background control (gray). Lines are
best-ﬁt curves and shaded areas represent 95% conﬁdence levels for the lines. Note that R2ORs are enriched near TSSs of upregulated genes. Similar
results were obtained for genes whose expression changed after 48h of Runx2 induction (Supplementary Figure S4).
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Figure 3. DNA sequence motifs enriched in R2ORs. Motifs enriched
in R2ORs compared to 1603 matched random sequences were identiﬁed
using HOMER 3.1. (A) Logo for the top motif (Runx2) is shown above
the Runx1 logo identiﬁed by Pencovich et al. (35). (B) Motifs identiﬁed
after R2ORs were re-analyzed as in A following masking of the Runx2
motifs. (C) Motif statistics. P-values are for motif enrichment. The
percentages of R2ORs containing at least one copy of each motif are
indicated against the percentage of motif-containing random sequences.
Motifs/R2OR indicates for each motif the average number of copies per
R2OR in R2ORs containing at least one copy.
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pro-metastatic property of Runx2.
DISCUSSION
Runx2 regulates many genes and pathways promoting
metastatic properties such as invasiveness, extravasation,
angiogenesis, osteolysis and drug resistance (5,14,52).
The present study demonstrates a role for Runx2 in
regulating protein secretion by PCa cells (Figure 6). The
hypothesis that Runx2 regulates secretion was based on
the association of this cellular function with a set of 98
Runx2-stimulated genes with nearby Runx2-occupied
regions (R2ORs). Such hypothesis was not invoked
when the Runx2 transcriptome was originally analyzed
by Ingenuity Pathway Analysis (14), or when re-analyzed
in this study by DAVID without regard to R2ORs
(Supplementary Table S7). Interestingly, the association
of Runx2-regulated genes with R2ORs was found for
up- but not down-regulated genes (Figure 4 and
Supplementary Figure S4). Lack of R2OR enrichment
near Runx2-downregulated genes suggests that their in-
hibition by Runx2 is likely a secondary event.
Our ChIP-seq results for Runx2 in PCa cells share
many features with those described for Runx1 in
megakaryocytes and in hematopoietic progenitor cells
(35,36). Both transcription factors bind mostly at regions
far from gene promoters, likely enhancers that form
shortcut loops to contact distant TSSs, up to hundreds
of kilo-bases away. Whereas extraordinary efforts are
needed to map such long-range interactions between en-
hancers and promoters, shorter-range interactions are sug-
gested by the excess of R2ORs within 40kb of TSSs of
Runx2-upregulated genes. Such shorter-range interactions
may be preferentially utilized by Runx2 in PCa cells to
execute deﬁned biological functions such as cell motility
and protein secretion (Supplementary Table S5). It will be
interesting to know if Runx1-upregulated genes with
nearby Runx1-occupied regions (R1ORs) execute deﬁned
A
BC D
Figure 5. Evidence that Runx2 directly stimulates genes associated with membrane trafﬁcking and secretion. (A) The 98 Runx2-upregulated genes
with nearby R2ORs were analyzed using DAVID for functional annotation. Top functions with fold enrichment >5 and P<0.05 are listed in
Supplementary Table S5, and those related to membrane trafﬁcking and secretion are listed in A, along with the speciﬁc Runx2-stimulated genes in
each functional category. (B) ChIP-seq results showing R2ORs near the TSSs (arrows) of three Rab genes. (C) ChIP-qPCR validation of R2ORs
indicated in B by black bars. (D) RT-qPCR analysis of the effects of Runx2 on the mRNA expression of RAB3B, RAB35 and RAB43. Primers used
in C and D are listed in Supplementary Table 1 (mean±SEM; n=3).
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Figure 6. Runx2 increases protein secretion by PCa cells. (A) Proteins
were precipitated from media conditioned by dox-treated and control
C4-2B/Rx2
dox cells, resolved in SDS–PAGE and stained by Coomassie
Blue. Proteins in the region indicated by a bracket were analyzed by
mass spectrometry and those identiﬁed with >95% conﬁdence are listed
in Supplementary Table S6. (B) Western blot analysis of the indicated
proteins in conditioned media or whole cell extracts from control and
dox-treated C4-2B/Rx2
dox cultures.
3544 Nucleic Acids Research, 2012,Vol.40, No. 8biological functions in hematopoietic progenitor cells or in
megakaryocytes (35,36). Additional similarities between
the Runx2 and the Runx1 ChIP-seq results relate to the
DNA motifs enriched within the respective occupied
regions. The motif most signiﬁcantly enriched in R2ORs,
YTGTGGTTW, is almost identical to that found in
R1ORs in hematopoietic cells (35). Finally, both the
R1ORs and the R2ORs were enriched for GATA and
ETS factors, indeed both also show evidence of a Runx/
Ets hybrid motif (37).
Using the dox-inducible system for Runx2 expression,
we observed cyclical genomic occupancy of Runx2 (Figure
1B). It remains to be seen whether such behavior, which
has been observed for ligand-activated transcription
factors such as the estrogen receptor (53,54), is shared
by Runx1, Runx3 or other TFs not activated by ligand.
It will also be interesting to know whether the composition
of Runx2-containing complexes changes between cycles of
occupancy. Be that as it may, the robustness of the
ChIP-seq peaks (Figures 1A and 5B) is attributable in
part to synchronization of Runx2 binding after dox treat-
ment, as well as the Flag-ChIP-seq approach that
mitigated the requirement for high quality antibodies
against Runx2 (55–58).
Runx2 stimulated the secretion of many proteins by
PCa cells, among which were the laminins a5 and ß1.
Because laminin g1 is also secreted by C4-2B/Rx2
dox
cells, the data suggest that Runx2 may render prostate
cancer cells able to synthesize the a5b1g1 laminin heter-
otrimer, also known as 511. Laminin 511 is abundant in
malignant tumors, blood vessels and bone and has been
implicated in guiding cancer cell metastasis as well as
promoting aggression of breast, prostate and other
cancer cells through activation of integrin signaling
(51,59–63). Interestingly, integrin signaling is also
enriched in the 98 upregulated genes with nearby
R2ORs (Supplementary Table S5). Thus, via direct
target genes, Runx2 may manipulate the cell microenvir-
onment through the secretion of laminins, while augment-
ing cellular response through expression of the respective
membrane signaling proteins.
In conclusion, Runx2 occupies sites in the PCa cell
genome that are enriched for the canonical TGTGGT-
containing Runx consensus motif and are usually
located far from TSSs of annotated genes. A set of pre-
sumably direct Runx2-upregulated genes was identiﬁed
based on proximity to R2ORs. These genes likely
mediate both known and novel metastatic properties of
Runx2, namely, cell motility and protein secretion.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online: Suppl-
ementary Tables 1–7 and Supplementary Figures 1–5.
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